Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies - Concepedia

Concepedia

Publication | Closed Access

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

181

Citations

15

References

2009

Year

Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, Craig H. Moskowitz, Debra Sarasohn, Ellen Neylon, Jill Mastrella, Rachel Hamelers, Barbara MacGregor‐Cortelli,

Journal of Clinical Oncology

Abstract

Pralatrexate has significant single-agent activity in patients with relapsed/refractory T-cell lymphoma.

References

	Year	Citations

Page 1